Drug Profile

PS 001

Alternative Names: PS-001 - Purespring Therapeutics

Latest Information Update: 07 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Purespring Therapeutics
Class Gene therapies; Urologics
Mechanism of Action Gene transference; NPHS2 protein replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Nephrotic syndrome

Most Recent Events

27 Oct 2025 Chromatin Bioscience and Purespring Therapeutics enters into a collaboration for chromatinLENS platform
30 May 2024 Pharmacodynamics and adverse events data from the preclinical studies in Nephrotic syndrome release by Purespring Therapeutics
24 May 2024 Preclinical trials in Nephrotic syndrome in United Kingdom (Parenteral) before May 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com